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Abstract 
Nanoscale size controllable and surface modifiable Zeolitic Imidazolate Framework-8 (ZIF-8)-
Poly(acrylic acid sodium salt) (PAAS) nanocomposites are fabricated by employing PAAS 
nanospheres as a soft template. These ZIF-8-PAAS nanocomposites have different sizes 
ranging from 30 to 200 nm and exhibit different crystallinity, and pH sensitivity. These 
nanocomposites can be employed as vectors to deliver doxorubicin (DOX) for anticancer 
therapy, leading to greatly enhanced drug therapeutic efficacy when tested in cell lines and mice 
model. Systematic toxicity investigation including hematoxylin and eosin staining analysis of 
tumor and major organs, hematology analysis and blood chemistry analysis indicates that the 
nanocomposites possess high biocompatibility. This work provides a strategy to make metal-
organic frameworks (MOFs) nanocomposites with size tunability in nanoscale and flexible 
surface modification for various applications. 
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1. Introduction 
Crystalline metal-organic frameworks (MOFs) are fabricated by reticular synthesis, in which 
strong bonds are formed between metal ions (inorganic) and organic linker molecules.1,2 As an 
emerging crystalline material, MOFs exhibit up to 90% free volume porosity and possess a 
surface area of over 6000 m2/g.3 With extraordinary flexibility of selection of organic and 
inorganic components (more than 20,000 kinds), MOFs can be rationally tuned with versatile 
structure, surface area, pore size and property.4-7 Because of these superior characteristics, 
MOFs have been widely used for air purification,8-10 gas separations/storage,11-14 chemical 
sensors,15,16 heterogeneous catalysis,17-20 and biomedical engineering21-28. 
For many applications, it is of great importance to rationally design MOFs with optimal 
surface chemistry and size tunability. Taking drug delivery as an example, MOFs were first 
used as a drug carrier in 2006.29,30 Since then, MOFs have been developed to nanoregime of 
below 200 nm for improved drug delivery and bioimaging because materials within this size 
range can have high cellular uptake and long blood-circulation time31,32 and these make them 
good candidates as drug carriers.33-38 Despite the progress in recent years of using nanoscale 
MOFs (NMOFs) for drug delivery, negligible work has been reported to produce size 
controllable NMOFs. Very recently, Park et al. reported to produce size controllable (30-190 
nm) Zr(IV)-based porphyrinic MOFs by adjusting the concentration of reactant benzoic acid. 
The results demonstrated that the MOFs with a size of 90 nm have significantly higher cellular 
uptake and in vivo photodynamic therapy efficacy when used to deliver a photosensitizer than 
those of other sizes.39 However, the specific parameters controlling the size of MOFs need to 
be tuned for each type of material. Beyond size controllability, the surface of nanomaterials 
plays an important role in biological and medical applications. Currently, stabilization of MOFs 
in aqueous solution is predominantly relying on surface coating, but the conventional polymer 
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or silica coating may block the pores on the surface of MOFs, leading to decrease of porosity 
and correspondingly drug loading capacity.40  
To address these bottlenecks of making size controllable and surface tunable NMOFs for 
efficient drug delivery, herein, we propose a method of employing poly(acrylic acid sodium 
salt) (PAAS) nanospheres as a soft template to produce size controllable and surface modifiable 
zeolitic imidazolate framework-8 (ZIF-8)-poly(acrylic acid sodium salt) (PAAS) 
nanocomposites. In this unique approach, we hypothesize that the particle size can be precisely 
controlled by the molecules weight of PAAS soft template; and instead of directly modifying 
MOFs for stabilization, the surface modification may be constructed on the PAAS template. To 
confirm our hypothesis, we systematically studied the approach of using PAAS as templates 
for synthesizing NMOFs with controllable sizes of below 200 nm and establishing desirable 
surface modification on PAAS. Through extensive studies, we found that surface modification 
molecules should be conjugated to PAAS first and then use the conjugated polymer as a 
template for MOFs growth. In this way, NMOFs with high stability and cancer cell targeting 
ability can be conveniently synthesized. Because surface modification was performed to the 
PAAS template, it is expected that the high porosity of NMOFs and corresponding drug loading 
capacity can be retained without being negatively affected by surface modification. To the best 
of our knowledge, such an approach of using PAAS of different molecular weights to produce 
NMOFs with size controllability and desirable surface modification has not been reported. After 
successful preparation of NMOFs, the size, morphology, structure, drug loading and release 
under different conditions, in vitro cancer cell killing efficiency, and in vivo tumor inhibition 
rate and biosafety profiles were investigated in detail. The experimental results demonstrate 
that these NMOFs possess superior characteristics of high drug loading capacity, pH responsive 
drug release, excellent tumor inhibition efficacy, and great biocompatibility. Overall, this soft-
template method provides a powerful approach to fabricate size and surface controllable 
NMOFs for high performance applications. 
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2. Experimental section 
2.1 Materials and Characterization 
PAAS (Mw=20k), isopropyl alcohol and methanol were purchased from International 
Laboratory (U.S.A.). Zn(NO3)2 and 2-methylimidazole were ordered from Acros (U.S.A.). 
PAAS (Mw=8K), PAAS (Mw=1.2K) and polyethylene glycol (PEG)-Amine (Mw=5000) were 
bought from Sigma-Aldrich (U.S.A.). Doxorubicin (DOX) was from Beijing Zhongshuo 
Pharmaceutical Technology Development Co., Ltd (China). Dulbecco’s modified eagle 
medium (DMEM), fetal bovine serum (FBS), phosphate-buffered saline (PBS), MTT (3-(4,5-
Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide), penicillin/streptomycin, Hoechst 
33342 were obtained from Life Technologies (U.S.A.). 96-well cell culture plates and cell 
culture dishes were obtained from Corning (U.S.A.). Zeta potential and size distribution were 
measured by Zetasizer (Malvern). Transmission electron microscopy (TEM) and high-
resolution transmission electron microscopy (HRTEM) images were taken on Technai 12 
(Philips) and JEOL JEM 2100F, respectively. Scanning electron microscopy (SEM) images 
were taken on FEG SEM-XL30. Powder X-ray diffraction (XRD) patterns were collected with 
D2 Phaser X-ray diffraction using Cu-Ka radiation.  
2.2 PAAS Nanosphere Fabrication  
PAAS (Mw 1.2K, 8K and 20K) solutions were first diluted to 0.2 g/mL and then 200 µL of 
the diluted PAAS solutions (Mw 1.2K, 8K and 20K) were added separately into 4 mL of Mini-
Q water (18.2 mΩ) with 5 minutes stirring. Subsequently, 20, 40, and 80 mL of isopropyl 
alcohol were added into PAAS solutions with molecular weights of 1.2, 8, and 20K, 
respectively with magnetic stirring for making different sizes of PAAS templates. 
2.3 ZIF-8-PAAS Nanocomposites Fabrication  
The as-prepared PAAS nanospheres were mixing with 6.7 mL of 0.1M Zn(NO3)2 in 
methanol solution under stirring for 5 minutes. Then, the mixture was centrifuged at 2000, 4000, 
and 6000 rpm for PAAS with Mw 1.2K, 8K and 20K, respectively. Next, the precipitated PAA-
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Zn nanospheres were re-dispersed in 20 mL of methanol, followed by addition of 20 mL of 20 
mg/mL 2-methylimidazole in methanol under stirring. Finally, the solution was subjected to 
reaction at 70 oC for 12 hours. 
2.4 PEG Modified ZIF-8 Nanocomposites Fabrication 
First, 300 µL of 0.2 g/mL PAAS (Mw 8K) solution and 1.5 mL of 2 mg/mL PEG-Amine 
were sequentially added into 1.5 mL of Mini-Q water (18.2 mΩ), followed by overnight stirring 
in presence of EDC as a catalyst. Second, 3 mL of Mini-Q water and 24 mL of isopropyl alcohol 
were added into the solution with magnetic stirring. Third, 8 mL of 0.1M Zn(NO3)2 in methanol 
solution was added and stirred for 5 minutes. Fourth, the mixture was centrifuged at 10000 rpm 
for 30 minutes. Fifth, the precipitation was re-dispersed in 4 mL of methanol, followed by 
addition of 16 mL of 20 mg/mL 2-methylimidazole in methanol under active stirring. Finally, 
the solution was subjected to reaction at 70 oC for 12 hours. 
2.5 Drug Loading Capacity and Loading Efficiency 
400, 200, 100, 50 and 25 µL of 2 mg/mL ZIF-8 NMOFs nanocomposites solution were 
added into 200 µL of 2 mg/mL DOX solution, and the mixture was under stirring for 24 hours. 
The amount of drug loading was determined from the absorbance differences (@480nm) of 
DOX in the solution before and after mixing with ZIF-8 NMOFs nanocomposites. Loading 
capacity and loading efficiency were calculated by following equations: (1) Loading 
capacity=(W t-W f)/Wn*100%; (2) Loading efficiency=(W t-W f)/Wt*100%; Where W t is the 
total DOX in solution; W f the free DOX after loading; Wn the weight of ZIF-8 NMOFs 
nanocomposites. 
2.6 In Vitro DOX Release Profile  
DOX loaded ZIP-8 NMOFs nanocomposites were added into 2 mL of buffer solution 
(pH=7.4 and pH=5) placed on a shaking water bath at 37 oC. After different time intervals, 120 
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µL of the buffer solution was collected and the amount of DOX release was measure by 
absorbance at 480 nm. 
2.7 Fluorecence Microscopy  
HeLa cell suspension was seeded onto a sterile glass coverslip in a 35 mm tissue culture 
dish for 24 hours. Then the cell culture medium was replaced with a fresh medium containing 
DOX loaded ZIF-8 NMOFs nanocomposites (10 wt% DOX) at DOX concentration of 4 µg/mL. 
At 4 hours after incubation, the nuclei were stained by Hoechst 33342, and the coverslip was 
mounted onto a glass slide for fluorescence microscopy. 
2.8 Cell viability measurement  
HeLa cells were washed twice with PBS. HeLa cells suspended in DMEM (with 10% FBS, 
1% penicillin/streptomycin) were plated into 96-well plates (100 μL DMEM, and 1,500-3,000 
cells per well). The cells were incubated at 37 °C for 24 hours before further treatment. Then, 
another 100 μL DMEM containing various concentrations of DOX, ZIF-8 NMOFs 
nanocomposites and DOX loaded ZIF-8 NMOFs nanocomposites were added into 96-well 
plates for additional 48 and 72 hours incubation. After incubation, the original medium in each 
well was removed. Subsequently, 180 μL of DMEM (without FBS) and 20 μL of MTT stock 
solution (5 mg/ mL in PBS) were added and incubated for 4 hours. Then the medium containing 
MTT was completely removed, followed by adding 200 μL of DMSO to each well. Cell 
viabilities were determined by reading the absorbance of the plates at 540 nm using a BioTek 
Powerwave XS microplate reader. 
2.9 In vivo cancer therapy  
Tumor model was developed by injection of 4T1 cells to Balb/C mice (2.5×106 4T1 cells 
in 100 µL of PBS). At 7 days after inoculation of the cancer cells, the mice were randomly 
divided into 4 groups n=4 (defined as treatment Day 1). Then 200 μL of different drug 
formulations at a dose of 2.5 mg/mL DOX (referred to as MOF-DOX PEG, MOF-DOX and 
DOX) and PBS solution were injected into the different groups of mice via the tail vein on 
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treatment Day 1, 7, 13 and 19. The tumor size and body weight were monitored at 3 days 
interval until Day 22. The tumor size was calculated according to the equation: Volume = 
(Tumor length)*(Tumor width)2/2. Then, major organs including heart, liver, spleen, lung, and 
kidney as well as tumor were harvested. All tissues were fixed in a 10% formalin solution, 
embedded in paraffin, sectioned, and stained with hematoxylin and eosin (H&E) for analysis. 
All experiments were performed in compliance with the National Act on the Use of 
Experimental Animals (China) and the guidelines issued by Sichuan Province and Chengdu 
University. All experiments were approved by the Animal Ethics Committee of Chengdu 
University. 
3. Results and Discussion 
3.1 ZIF-8 NMOFs Nanocomposites Preparation and Characterization 
In our study, PAAS nanospheres were synthesized by a deionized water-isopropyl alcohol 
approach.41 PAAS with three different molecular weights (Mw) of 1.2K, 8K and 20K were 
chosen in the preparation. We found that PAAS nanospheres of different sizes of 105, 79 and 
33 nm were formed by self-assembly from PAAS with Mw of 1.2K, 8K and 20K, respectively. 
The sizes of nanospheres were measured by dynamic light scattering (DLS). (Supporting Figure 
S1,) SEM also confirms that PAAS nanospheres sizes are around 80 and 35 nm for PAAS with 
Mw of 8K and 20K, respectively. (Supporting Figure S2 and Figure S3) Because Zn2+ has higher 
affinity towards -COO- groups in PAAS polymer chains than Na+, PAAS nanospheres were 
mixed with Zn(NO3)2 at room temperature for 5 min so that Zn2+ could replace Na+. (Scheme 
1) The as-prepared PAA-Zn nanospheres were then reacted with 2-methylimidazole (2-MIMs) 
to form ZIF-8-PAAS crystal using the Zn2+ adsorbed on PAA-Zn nanopheres as Zn source. The 
size of ZIF-8-PAAS nanocomposites can be controlled from 200 and 90 to 30 nm by using 
PAAS nanosphere templates prepared from PAAS molecules with Mw of 1.2K, 8K and 20K, 
respectively. Depending on the molecular weight of the used PAAS, the produced 
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nanocomposites are denoted as ZIF-8 (1.2K), ZIF-8 (8K) and ZIF-8 (20K). The corresponding 
TEM images are presented in Figure 1a-c. The SEM images in Supporting Figure S4 show that 
ZIF-8 NMOFs nanocomposites fabricated from different PAAS nanospheres possess similar 
morphology. The sizes of these different ZIF-8 NMOFs nanocomposites were also confirmed 
by DLS analysis, which shows the diameters of ZIF-8 (1.2K), ZIF-8 (8K), and ZIF-8 (20K) 
particles are approximately 190, 98 and 46 nm, respectively. (Supporting Figure S5) The 
obtained ZIF-8 (1.2K), ZIF-8 (8K) and ZIF-8 (20K) NMOFs nanocomposites exhibit negative 
charge because of –COO- groups in the PAAS, which was measured by DLS analysis. 
(Supporting Figure S6) The Fourier transform infrared spectroscopy (FTIR) spectra show 
carbonyl stretching vibration of –COO- at 1580 cm-1 and stretching vibration of –COOH at 
1717 cm-1, which confirms the existence of –COO- groups in the nanocomposites. (Supporting 
Figure S7) 
 
 
Scheme 1. Schematic illustration of the approach of synthesizing ZIF-8 NMOFs 
nanocomposites using PAAS as a soft template. 
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Figure 1. a-c) TEM and d-f) HRTEM images of (a, d) ZIF-8 (1.2K), (b, e) ZIF-8 (8K), and (c, 
f) ZIF-8 (20K) NMOFs nanocomposites. 
 
To determine the crystal structure of ZIF-8 NMOFs nanocomposite, XRD was performed. 
(Supporting Figure S8) From the XRD pattern, one can observe that the diffraction patterns of 
ZIF-8 (1.2K), ZIF-8 (8K), and ZIF-8 (20K) nanocomposites have matched characteristic peaks, 
suggesting the formation of ZIF-8 crystals. The peaks of the XRD pattern of ZIF-8 (20K) are 
much sharper and stronger in intensity than those of ZIF-8 (1.2K) and ZIF-8 (8K). This 
indicates that ZIF-8 (20k) NMOFs nanocomposites possess higher crystallinity than ZIF-8 (8K) 
and ZIF-8 (1.2K) ones. To further investigate the difference in crystallinity, HRTEM was 
carried out. (Figure 1d-f and Supporting Figure S9) From the results, we can find that ZIF-8 
(1.2K), ZIF-8 (8K), and ZIF-8 (20K) nanocomposites contain crystalline region and amorphous 
area. Instead, ZIF-8 nanocrystals of a few nanometers are well-dispersed within the PAAS 
matrix. It is worth noting that, from the HRTEM images, ZIF-8 (20K) NMOFs nanocomposites 
possesses more well-aligned and larger crystalline region than ZIF-8 (8K), and ZIF-8 (1.2K) 
ones, which is in correspondence with the XRD results. Therefore, we can conclude that our 
method is able to control the crystallinity of fabricated ZIF-8 NMOFs nanocomposites. The 
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energy-dispersive X-ray spectroscopy (EDX) mapping images of ZIF-8 (1.2K) and ZIF-8 (8K) 
NMOFs nanocomposites demonstrate Zn element is well-distributed across the nanoparticles, 
confirming the relatively homogenous composition. (Supporting Figure S10 and Figure S11) 
3.2 In vitro study of ZIF-8 NMOFs nanocomposites 
After successful preparation of ZIF-8 NMOFs nanocomposites with different sizes, their 
drug loading and release capabilities were evaluated. DOX, a well-known anticancer drug, was 
used as a test case. DOX loading was achieved by simply mixing ZIF-8 NMOFs 
nanocomposites with DOX in an aqueous solution. Because the pore size of ZIF-8 is very small, 
DOX is physically adsorbed on the surface of ZIF-8 nanocomposite. We found that the drug 
loading capability of the three prepared ZIF-8 NMOFs nanocomposites was different. ZIF-8 
(1.2K) NMOFs nanocomposites show much better DOX loading capacity than ZIF-8 (8K) and 
ZIF-8 (20K) ones. (Figure 2a-b) When the mixing ratio of ZIF-8 NMOFs nanocomposites to 
DOX is 1:1, the loading efficiencies (weight of loaded DOX/weight of total DOX) are >97% 
for ZIF-8 (1.2K) and ZIF-8 (8K) and >87% for ZIF- 8 (20K). When the amount of DOX 
continually increases in the mixture (ZIF-8 to DOX ratios drop to 1:2, 1:4 and 1:8), the loading 
efficiency drops as the percentage of ZIF-8 NMOFs nanocomposites in the mixture becomes 
smaller. However, the loading capacity (weight of loaded DOX/weight of ZIF-8) keeps 
increasing. For example, when the ratio of ZIF-8 NMOFs nanocomposites to DOX is 1:8, every 
mg of ZIF-8 (1.2K), ZIF-8 (8K) and ZIF-8 (20K) can load 3.85 (385%), 3.14 (314%), and 1.73 
(173%) mg of DOX, with loading efficiency of 48%, 39% and 22%, respectively. These values 
indicate that our fabricated ZIF-8 NMOFs nanocomposites show very high drug loading 
capacity. Difference of drug loading capacity may be caused by the different crystallinity of 
different ZIF-8 NMOFs nanocomposites.  
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Figure 2. a) The loading capacities and b) loading efficiencies of DOX to ZIF-8 NMOFs 
nanocomposites at different mixing ratios (5 groups of ZIF-8 NMOFs nanocomposites to DOX 
ratios: 2:1, 1:1, 1:2, 1:4 and 1:8); c-d) The DOX release curves at pH 7.4 (physiological pH 
value) and pH 5 from ZIF nanocomposites with drug loading capacity of (c) 100 wt% and (d) 
10 wt%. 
Once confirming that our fabricated ZIF-8 NMOFs nanocomposites display excellent drug 
loading capacity, we next investigated their release kinetics. ZIF-8 (1.2K), ZIF-8 (8K) and ZIF-
8 (20K) NMOFs nanocomposites with drug loading capacity of 100 wt% (The weight of drug 
and ZIF-8 is equivalent) and 10 wt% (weight of drug/weight of ZIF-8 = 1:10) were selected for 
in vitro release study. (Figure 2c-d) Under pH 7.4, all ZIF NMOFs nanocomposites can hold 
DOX molecule relatively firmly for at least 24 hours, with only <15% (drug loading 100 wt%) 
and <30% (drug loading 10 wt%) of the loaded drugs released to the buffer solutions. However, 
when pH drops to 5 (the pH value of tumor tissue or lysosome), drug release becomes faster. 
Interestingly, these as-fabricated ZIF-8 NMOFs nanocomposites display different pH 
sensitivity. ZIF-8 (1.2K) is found to be more pH sensitive than ZIF-8 (8K) and ZIF-8 (20K). 
For example, ZIF-8 (1.2K) NMOFs nanocomposites with drug loading capacity of 100 wt% 
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releases greater 60% of DOX at pH 5, which is much higher than the other two nanocomposites. 
The possible explanation of the different pH sensitivity is due to the different crystallinity: ZIF 
(1.2K) NMOFs nanocomposites have less crystallinity than ZIF-8 (8K) and ZIF-8 (20K), 
resulting in lower stability in acid environments, and thus release of more DOX drug. This 
explanation was supported by TEM images of ZIF-8 nanocomposites after treatment in pH 7.4 
and pH 5 buffer solution. The structure of vast majority of ZIF-8 (1.2k), ZIF-8 (8K) and ZIF-8 
(20K) NMOFs nanocomposites collapses at pH 5, while their structure is relatively stable at pH 
7.4, particularly for ZIF-8 (8K) and ZIF-8 (20K); at pH 5, some ZIF-8 (20K) NMOFs 
nanocomposites can still maintain the structure. (Supporting Figure S12) In consistence with 
these findings observed from TEM, DLS shows the mean count rate of ZIF-8 (1.2k), ZIF-8 
(8K) and ZIF-8 (20K) NMOFs nanocomposites significantly drops to less than 20 kcps (almost 
background level) after pH 5 buffer treatment for 2 min. This means that the release of the drug 
from the MOFs is more efficient at a lower pH value. Overall, ZIF-8 (1.2K), ZIF-8 (8K), and 
ZIF-8 (20K) NMOFs nanocomposites display different size, crystallinity, drug loading capacity 
and pH sensitivity. (Table 1)  
Table 1. The summary of size and loading capacity of PAAS and ZIF-8 NMOFs 
nanocomposites. 
 PAAS 
(1.2K) 
PAAS  
(8K) 
PAAS  
(20K) 
PAAS Size (DLS) 105nm 79nm 33nm 
ZIF-8 Size (DLS) 190nm 98nm 46nm 
ZIF-8 Size (TEM) 200nm 90nm 30nm 
Drug Loading Capacity (wt%) 385 wt% 314 wt% 173 wt% 
 
Following the study of the release kinetics, the intracellular delivery of different sizes of 
ZIF-8 NMOFs nanocomposites loaded with DOX was studied, because the size of 
nanomaterials can dramatically affect their intracellular delivery efficiency. In this study, we 
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selected ZIF-8 NMOFs nanocomposites with DOX loading of 10 wt% to investigate the 
intracellular delivery efficiencies of the three different ZIF-8 NMOFs nanocomposites. The 
results are shown in Figure 3. It is apparent that the intracellular delivery efficiency is size 
dependent: ZIF-8 (1.2K) < ZIF-8 (8K) < ZIF-8 (20K). After 4 hours incubation, the HeLa cells 
treated with ZIF-8 (20K) (46 nm) NMOFs nanocomposites show much stronger fluorescence 
signal from DOX than those treated with ZIF-8 (1.2K) (190 nm) and ZIF-8 (8K) (98 nm) 
NMOFs nanocomposites. 
 
Figure 3. a-i) Fluorescence microscopy images of HeLa cells after 4 hours incubation with (a-
c) ZIF-8 (1.2K), (d-f) ZIF-8 (8K) and (g-i) ZIF-8 (20K) NMOFs nanocomposites loaded with 
10 wt% DOX. 
Subsequently, we characterized the HeLa cell viability after incubation with ZIF-8 (1.2K), 
ZIF-8 (8K) and ZIF-8 (20K) NMOFs nanocomposites for 48 and 72 hours. (Figure 4) Again, 
we chose ZIF-8 NMOFs nanocomposites with 10 wt% DOX loading for test. The results show 
that significantly improved delivery efficiency can be achieved with the aid of ZIF-8 NMOFs 
nanocomposites, particularly with the nanocomposite made from PAAS of molecular weight of 
20k Daltons. (Figure 4) This is well-matched with our data that ZIF-8 (20K) enter cells more 
efficiently than ZIF-8 (1.2K) and ZIF-8 (8K) NMOFs nanocomposites. For ZIF-8 (1.2K) and 
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ZIF-8 (8K) NMOFs nanocomposites, the drug efficacy is overall comparable to free DOX in 
cell lines, depending on the concentrations of the drug. However, we expect that the ZIF-8-
DOX can realize much better efficacy and smaller side effect in in vivo applications due to the 
enhanced permeability and retention (EPR) effect and the preferable release kinetics of 
nanomedicine. 
 
Figure 4. The viabilities of HeLa cells after 48 (a) and 72 (b) hours of incubation with free 
DOX and ZIF-8 (1.2K), ZIF-8 (8K), and ZIF-8 (20K) NMOFs nanocomposites loaded with 10 
wt% of DOX. 
3.3 In vivo study of ZIF-8 NMOFs Nanocomposites 
Once we know that ZIF-8 NMOFs nanocomposites have excellent properties and high cell 
killing efficiency, its application in in vivo anticancer therapy was next evaluated. In this study, 
ZIF-8 (8K) NMOFs nanocomposites were chosen as a drug delivery vector, because of its well-
balanced drug loading capacity, pH sensitivity and stability. In order to prolong the material’s 
blood circulation time, PEG (Mw=5000) was conjugated to PAAS (8K) molecule before 
nanocomposites fabrication. (Scheme 2) (Figure S13) Then for drug loading, 1 mL of 1 mg/mL 
of DOX was mixed with 1mL of 1 mg/mL of MOF-PEG nanocomposites for 24 hours. During 
this process, almost all DOX was able to be loaded to MOF-PEG nanocomposites. This is the 
advantage of our ZIF-8 nanocomposite. The reason is: PEG is conjugated to PAAS template 
instead of ZIF-8 nanocrystal and therefore it does not interfere subsequent drug loading. 
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Scheme 2. Schematic illustration of PEG modified ZIF-8 NMOFs nanocomposites formation 
using PAAS as a soft template. 
After drug loading, the biodistribution of MOF-PEG DOX nanocomposites in mice was 
investigated by using small animal in vivo fluorescence system to detect the fluorescence signal 
of DOX. (Supporting Figure S15) It was found that DOX can be effectively delivered to the 
tumor site within 24 hours, demonstrated the very bright DOX fluorescence signal. At 48 hours 
after injection, the fluorescence intensity in the tumor site further increases, while the 
fluorescence intensities in major organs including heart, liver, kidney, spleen, and lung start to 
drop.  
Since PEG modified MOF nanocomposites can effectively deliver DOX to tumor sites, it 
is expected that it can efficiently inhibit tumor growth. To verify this, a group of 5 mice was 
intravenously injected with MOF-PEG DOX (DOX dose at 2.5 mg/kg) and then the tumor 
volumes of mice were monitored for 22 days. In addition, for comparison purpose, 3 other 
groups of mice were injected with PBS, free DOX (DOX), and MOF loaded with DOX but 
without PEG modification (MOF DOX). The results are shown in Figure 5a. It is clear that the 
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therapeutic efficacy of free DOX molecules and the DOX delivered by MOF nanocomposites 
without PEG surface modification is very low, indicating by the rapid growing tumor during 
the observation period. In great comparison, MOF-PEG DOX constantly exhibits significantly 
improved therapeutic efficiency: more than 50% tumor reduction comparing with other 3 
groups. There is a statistical difference between MOF-PEG DOX and other three groups (p＜
0.05). Moreover, there is minimal weight loss in the group treated with MOF-PEG DOX (Figure 
5b), indicating that the PEG modified MOF with MTX has great therapeutic efficacy with good 
biocompatibility. In addition, H&E staining of tumor slices were also evaluated. From the H&E 
staining, higher tumor cell damage is shown in MOF-PEG DOX treated tumor, compared with 
MOF DOX, DOX and PBS treated groups, which confirms that MOF-PEG DOX has better 
anti-cancer efficiency (Figure 5c). 
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Figure 5.  In vivo anticancer activities: a). Tumor growth curves of 4T1 tumor bearing 
BALB/C mice after intravenous injection with 1). PBS, 2). DOX loaded by PEG modified ZIF-
8 NMOFs nanocomposites (MOF-PEG DOX), 3). DOX loaded by ZIF-8 NMOFs 
nanocomposites (MOF DOX), 4) free DOX ; b). The body weight evolution of 4T1 tumor-
bearing mice at different times after intravenous injection of different materials; c) H&E 
staining images of tumors slices. Scale bar: 100 μm. 
To investigate the mechanism of MOF-PEG DOX inhibition of tumor growth, 
immunohistochemistry analysis of Caspase-3, KI-67 and CD31 as well as Terminal 
deoxynucleotidyl transferased dUTP nick end labeling (TUNEL) was conducted. (Figure 6) 
Caspase-3, KI-67 and CD31 are the indicators for apoptosis, cell proliferation and tumor 
angiogenesis, respectively. In Figure 6, the mean optical density (MOD) for Caspase-3 
expression are 0.313±0.001, 0.300±0.006, 0.288±0.001 and 0.277±0.004 for MOF-PEG DOX, 
MOF DOX, DOX and PBS treated groups, respectively. The higher expression of Caspase-3 in 
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MOF-PEG DOX treated group indicates that MOF-PEG DOX induce higher cell apoptosis than 
MOF DOX and DOX, thereby causing the death of tumor cells. For quantity analysis, the cell 
apoptosis was also evaluated by TUNEL, which shows 73.3±4.04%; 34±7%; 69.0±2.6% and 
24.7±2.5% apoptosis cells in MOF-PEG DOX, MOF DOX, DOX and PBS treated groups, 
respectively. These confirm that MOF-PEG DOX can effectively kill tumor cell by inducing 
cell apoptosis. 
 
 
Figure 6. Immunohistochemistry (Caspase 3, KI67 and CD31 antibody) and TUNEL images 
of tumor slices. 4T1 tumor bearing BALB/C mice after intravenous injection with 1). DOX 
loaded by PEG modified ZIF-8 NMOFs nanocomposites (MOF-PEG DOX), 2). DOX loaded 
by ZIF-8 NMOFs nanocomposites (MOF DOX), 3) free DOX and 4). PBS. Yellow brown 
indicates positive; blue indicates negative. Scale bar: 40 μm. 
In addition, we evaluated the level of KI-67, which is a key indicator for cell proliferation. 
Dramatically lowered expression of KI-67 was detected in MOF-PEG DOX treated tumor 
(MOD=0.295±0.013) compared with MOF DOX (0.339±0.013), DOX (MOD=0.328±0.016) 
and PBS (MOD=0.345±0.008) treated groups, indicating enhanced inhibition of the cancer cell 
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proliferation. Finally, we analyzed CD31 protein, which is highly associated with tumor 
angiogenesis and tumor growth. In Figure 6, lower CD31 expression is presented in the MOF-
PEG DOX treated group, revealing that tumor growth was effectively inhibited. Microvascular 
density (MVD) was also counted (most vascularized area, every slice 5 hot spots were selected), 
which is highly associated with tumor metastasis and prognosis. The average MVD results are 
6.6±1.1; 12±1.6; 10.4±2.7 and 16.6±2 in MOF-PEG DOX, MOF DOX, DOX and PBS treated 
groups, respectively. The MVD counting confirms the effectiveness of MOF-PEG DOX for 
tumor growth inhibition. 
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Figure 7. H&E staining images of major organs (heart, liver, spleen, lung, and kidney). The 
mice were treated with DOX loaded by PEG modified ZIF-8 NMOFs nanocomposites, free 
DOX and PBS at Day 1 and sacrificed at Day 7. Scale bar: 200 μm. 
3.4 Biosafety study of ZIF-8 NMOFs Nanocomposites 
Biosafety is one of a major concern for clinical application of nanomedicine; therefore, we 
finally systematically investigated the toxicity of MOF-PEG DOX. Firstly, histopathological 
examinations (H&E staining) were conducted to analyze major organs, including heart, liver, 
spleen, lung and kidney. (Figure 7) From these H&E staining images, no obvious organ damage 
is shown in DOX and MOF-PEG DOX treated groups. Apparently, histopathological 
examinations demonstrate MOF-PEG DOX nanocomposites cause minimal toxicity to major 
organs. Because liver and kidney damage is a very common side-effect of therapeutic drugs, to 
investigate he biosafety of MOF-PEG DOX, the liver and kidney function (Figure 8) of the 
treated mice were evaluated by measuring the blood serum levels of alanine aminotransferase 
(ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), blood urea nitrogen 
(BUN), creatinine (CRE) and uric acid (UA). From the results, no obvious abnormality is found, 
indicating that MOF-PEG DOX nanocomposites have low toxicity towards liver and kidney, 
which is in line with our histopathological results. Since ZIF-8 NMOFs were intravenously 
injected, these drugs directly interacted with blood. Therefore, blood chemistry analysis was 
performed. There is also no significant abnormality of the complete blood counts data, 
including red blood cells (RBC), white blood cells (WBC), hemoglobin (HGB), hematocrit 
(HCT), mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), mean 
corpuscular hemoglobin concentration (MCHC), and platelet count (PLT) (Figure S16). Overall, 
all of these toxicity profiles suggest that MOF-PEG DOX have high biosafety for in vivo cancer 
therapy. 
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Figure 8. Liver function (ALT, AST and ALP) and Kidney function (BUN , CRE and UA) of 
healthy mice. The mice were treated with (A) PBS, (B) free DOX, (C) PEG modified ZIF-8 
NMOFs nanocomposites at Day 1 and sacrificed at Day 7. The normal ranges of ALT, AST, 
ALP, BUN, CRE and UA are 33.0-99.0, 69.5-210.0, 40.0-190.0, 2.00-7.70, 22.0-97.0 and 20-
420, respectively. 
4. Conclusion 
In summary, we have developed a strategy of using PAAS as a soft template to prepare 
size controllable and surface modifiable ZIF-8-PAAS nanocomposites in the range of 30-200 
nm which is suitable for drug delivery. The as-fabricated nanocomposites have ultra-high drug 
loading capacity of up to 385 wt%. We also demonstrate that the nanocomposites fabricated 
from different PAAS nanospheres have different crystallinity, drug loading capacity and release 
kinetics, and pH sensitivity. Also vey importantly, these nanocomposites can be conveniently 
modified with functional molecules. As a test case, these nanocomposites were functionalized 
with PEG and employed as vectors to deliver DOX for cancer therapy with greatly enhanced 
efficacy in vitro and in vivo. Thus, this work provides a strategy to fabricate NMOFs 
nanocomposites with size tunability and flexible surface chemistry for various applications. 
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Figure S1.  Particle size distributions of (a) PAAS nanospheres (1.2K), (b) PAAS 
nanospheres (8K), and (c) PAAS nanospheres (20K).  
 
 
 
 
 
Figure S2. (a, b) SEM images of PAAS nanospheres (8K).  
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Figure S3. (a, b) SEM images of PAAS nanospheres (20K). We were unable to capture 
SEM images of PAAS nanospheres with Mw of 1.2K. The reason may be that the 
nanospheres made from PAAS with Mw of 1.2K are extremely unstable, and the 
nanosphere structure collapses during the drying period. 
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Figure S4. SEM images of (a) ZIF-8 (1.2K), (b) ZIF-8 (8K), and (c) ZIF-8 (20K) 
nanocomposites.  
Figure S5.  Particle size distributions of (a) ZIF-8 (1.2K), (b) ZIF-8 (8K), and (c) ZIF-
8 (20K) nanocomposites. 
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Figure S6.  Zeta potential of (a) ZIF-8 (1.2K), (b) ZIF-8 (8K), and (c) ZIF-8 (20K) 
nanocomposites. 
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Figure S7. The Fourier transform infrared spectroscopy of ZIF-8 (1.2K), ZIF-8 (8K) 
and ZIF-8 (20K) nanocomposites. 
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Figure S8. The powder X-ray diffraction patterns of ZIF-8 (1.2K), ZIF-8 (8K) and ZIF-
8 (20K) nanocomposites, as well as ZIF-8. 
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Figure S9. HRTEM images of (a) ZIF-8 (1.2K), (b) ZIF-8 (8K), and (c) ZIF-8 (20K) 
nanocomposites.  
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Figure S10. (a,c) Scanning TEM images of ZIF-8 (1.2K) nanocomposites, and (b,d) 
corresponding EDX mapping images of Zn.  
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Figure S11. (a,c) Scanning TEM images of ZIF-8 (8K) nanocomposites, and (b,d) 
corresponding EDX mapping images of Zn.  
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Figure S12. TEM images of (a), (d) ZIF-8 (1.2K); (b), (e) ZIF-8 (8K), and (c), (f) ZIF-
8 (20K) nanocomposites after 2 hours of (a-c) pH=7.4 PBS and (d-f) pH=5.0 buffer 
solution treatment; (f): For ZIF-8 (20K), after 2 hours treatment at pH of 5.0, a very 
small number of particles can be observed. 
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Figure S13. Characterization of PEG modified ZIF-8 NMOFs nanocomposites: (a) 
SEM, (b) TEM and (c) XRD Pattern. 
 
S-13 
 
 
Figure S14. The demonstration of successful conjugation of PEG to ZIF-8 
nanocomposite. (In order to demonstrate successful conjugation of PEG to ZIF 
nanocomposites, we labelled PEG with FITC to track PEG molecules after reaction. In 
the experiment, FITC labelled PEG molecules were mixed with ZIF-8 nanocomposites; 
after reaction, the nanocomposites were centrifuged. If PEG was not successfully 
conjugated to the nanocomposites, the fluorescent PEG molecules would be remained 
in the solvent. It was found that almost all fluorescence signal was from the precipitated 
ZIF-8 NMOFs nanocomposites, indicating the successful conjugation of PEG to ZIF-8 
nanocomposites.) 
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Figure S15. Biodistribution of MOF-PEG DOX. (Signal from Dox) 
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Figure S16. The complete blood counts data: RBC, WBC, HGB, HCT, MCV, MCH, 
MCHC and PLT. The mice were treated with (A) PBS, (B) free DOX, (C) PEG 
modified ZIF-8 nanocomposites at Day 1 and sacrificed at Day 7. The normal ranges 
of RBC, WBC, HGB, HCT, MCV, MCH, MCHC and PLT are 2.20-15.00, 2.3-31.6, 
40-174, 0.200-0.400, 44.0-66.5, 13.0-23.0, 270-520 and 270-1100, respectively. 
 
 
